Quest Diagnostics narrows FY24 adjusted EPS view to $8.85-$8.95 from $8.80-$9.00

Consensus $8.85. Raises FY24 revenue view to $9.8B-$9.85B from $9.5B-$9.58B, consensus $9.67B. Backs FY24 capital expenditures view $420M. “We have increased our 2024 revenue guidance due to contributions from recent acquisitions and have maintained the midpoint of our adjusted EPS guidance despite the impact of Hurricane Milton in the fourth quarter,” Davis continued. “Given the strength of our business and revenue from acquisitions, we are well positioned to drive accelerated revenue and earnings growth in 2025.”